Two FDA rebukes are so uncommon that it appears so
Post# of 148147
(Total Views: 544)
Posted On: 02/25/2022 4:22:09 PM
Two FDA rebukes are so uncommon that it appears someone at the agency was very upset about something, or some one, at Cytodyn.
My belief is that one or more people at the FDA were perturbed with some of the statements made by Pourhassan, as well as his showboating style.
If Cytodyn hires someone who has biopharma experience, and good credibility, I think FDA will change its position, and treat the company, and Leronlimab, more fairly.
I would be curious as to your take as to why you think the company suddenly terminated Pourhassan without having a replacement ready to take over.
I would also be curious as to your take as to what qualifications the new CEO should have, and what caliber of CEO the company will be able to hire given its precarious financial situation, and the ongoing SEC and DOJ investigations.
My belief is that one or more people at the FDA were perturbed with some of the statements made by Pourhassan, as well as his showboating style.
If Cytodyn hires someone who has biopharma experience, and good credibility, I think FDA will change its position, and treat the company, and Leronlimab, more fairly.
I would be curious as to your take as to why you think the company suddenly terminated Pourhassan without having a replacement ready to take over.
I would also be curious as to your take as to what qualifications the new CEO should have, and what caliber of CEO the company will be able to hire given its precarious financial situation, and the ongoing SEC and DOJ investigations.
(2)
(1)CytoDyn Inc (CYDY) Stock Research Links
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
Scroll down for more posts ▼